Imagine diagnosing cancer, even what specific type of cancer, non-invasively. This is especially important in the Lung, where biopsies and surgeries have high morbidity and mortality rates. RevealDx is a Seattle-based software company whose mission is dramatically improve lung cancer outcomes using non-invasive diagnosis. We are delivering the most advanced, radiomics and AI-enabled, lung cancer decision support software in the world. Click below to learn more.
Clinicians can be confident that their performance will be better if they include mSI in their assessment.
A single click is all that is needed to compute the mSI, and the results are displayed within a few seconds.
Cost can be dramatically decreased by reducing unnecessary procedures.
RevealDx Announces Distribution Agreement and Investment from 4DMedical 4DMedical to Distribute RevealAI-Lung in the US, Europe, Australia and New Zealand Seattle, WA – August 3, 2026 – RevealDx, a leader in AI characterization of lung nodules, announced today, following World Lung Cancer Day, a distribution agreement and strategic investment of $3.4 million by 4DMedical (ASX: … RevealDx Announces Distribution Agreement and Investment from 4DMedical
[ MORE ]Nashville, TN and Seattle, WA – May 14, 2026 – Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, and RevealDx, the leader in AI tools for the characterization of lung nodules, today announced a new partnership. This partnership builds upon Azra AI’s recent acquisition of Thynk health, which provides … Azra and RevealDx Announce Partnership
[ MORE ]
